Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Plasmonic gadolinium oxide nanomatryoshkas: bifunctional magnetic resonance imaging enhancers for photothermal cancer therapy.

ABSTRACT: Nanoparticle-assisted laser-induced photothermal therapy (PTT) is a promising method for cancer treatment; yet, visualization of nanoparticle uptake and photothermal response remain a critical challenge. Here, we report a magnetic resonance imaging-active nanomatryoshka (Gd₂O₃-NM), a multilayered (Au core/Gd₂O₃ shell/Au shell) sub-100 nm nanoparticle capable of combining T₁ MRI contrast with PTT. This bifunctional nanoparticle demonstrates an r₁ of 1.28 × 10⁸ mM^-1 s^-1, an MRI contrast enhancement per nanoparticle sufficient for T₁ imaging in addition to tumor ablation. Gd₂O₃-NM also shows excellent stability in an acidic environment, retaining 99% of the internal Gd(3). This report details the synthesis and characterization of a promising system for combined theranostic nanoparticle tracking and PTT.

SUBMITTER: Henderson L

PROVIDER: S-EPMC9802487 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Plasmonic gadolinium oxide nanomatryoshkas: bifunctional magnetic resonance imaging enhancers for photothermal cancer therapy.

Henderson Luke L Neumann Oara O Kadria-Vili Yara Y Gerislioglu Burak B Bankson James J Nordlander Peter P Halas Naomi J NJ

PNAS nexus 20220729 4

Nanoparticle-assisted laser-induced photothermal therapy (PTT) is a promising method for cancer treatment; yet, visualization of nanoparticle uptake and photothermal response remain a critical challenge. Here, we report a magnetic resonance imaging-active nanomatryoshka (Gd2O3-NM), a multilayered (Au core/Gd2O3 shell/Au shell) sub-100 nm nanoparticle capable of combining T1 MRI contrast with PTT. This bifunctional nanoparticle demonstrates a ...[more]

PMID: 36714874

Similar Datasets

Gadolinium-Chelated Conjugated Polymer-Based Nanotheranostics for Photoacoustic/Magnetic Resonance/NIR-II Fluorescence Imaging-Guided Cancer Photothermal Therapy.

Project description:Our exploiting versatile multimodal theranostic agent aims to integrate the complementary superiorities of photoacoustic imaging (PAI), second near-infrared (NIR-II, 1000-1700) fluorescence and T1-weighted magnetic resonance imaging (MRI) with an ultimate objective of perfecting cancer diagnosis, thus improving cancer therapy efficacy. Herein, we engineered and prepared a water-soluble gadolinium-chelated conjugated polymer-based theranostic nanomedicine (PFTQ-PEG-Gd NPs) for in vivo tri-mode PA/MR/NIR-II imaging-guided tumor photothermal therapy (PTT). Methods: We firstly constructed a semiconducting polymer composed of low-bandgap donor-acceptor (D-A) which afforded the strong NIR absorption for PAI/PTT and long fluorescence emission to NIR-II region for in vivo imaging. Then, the remaining carboxyl groups of the polymeric NPs could effectively chelate with Gd3+ ions for MRI. The in vitro characteristics of the PFTQ-PEG-Gd NPs were studied and the in vivo multimode imaging as well as anti-tumor efficacy of the NPs was evaluated using 4T1 tumor-bearing mice. Results: The obtained theranostic agent showed excellent chemical and optical stability as well as low biotoxicity. After 24 h of systemic administration using PQTF-PEG-Gd NPs, the tumor sites of living mice exhibited obvious enhancement in PA, NIR-II fluorescence and positive MR signal intensities. Better still, a conspicuous tumor growth restraint was detected under NIR light irradiation after administration of PQTF-PEG-Gd NPs, indicating the efficient photothermal potency of the nano-agent. Conclusion: we triumphantly designed and synthesized a novel and omnipotent semiconducting polymer nanoparticles-based theranostic platform for PAI, NIR-II fluorescence imaging as well as positive MRI-guided tumor PTT in living mice. We expect that such a novel organic nano-platform manifests a great promise for high spatial resolution and deep penetration cancer theranostics.

| S-EPMC6592180 | biostudies-literature

Fabricating Dual-Functional Plasmonic-Magnetic Au@MgFe2O4 Nanohybrids for Photothermal Therapy and Magnetic Resonance Imaging.

Project description:Bifunctional nanohybrids possessing both plasmonic and magnetic functionalities are of great interest for biomedical applications owing to their capability for simultaneous therapy and diagnostics. Herein, we fabricate a core-shell structured plasmonic-magnetic nanocomposite system that can serve as a dual-functional agent due to its combined photothermal therapeutic and magnetic resonance imaging (MRI) functions. The photothermal activity of the hybrid is attributed to its plasmonic Au core, which is capable of absorbing near-infrared (NIR) light and converting it into heat. Meanwhile, the magnetic MgFe2O4 shell exerts its ability to act as a MRI contrast agent. Our in vivo studies using tumor-bearing mice demonstrated the nanohybrids' excellent photothermal and MRI properties. As a photothermal therapeutic agent, the nanohybrids were able to dramatically shrink solid tumors in mice through NIR-induced hyperthermia. As T 2-weighted MRI contrast agents, the nanohybrids were found capable of substantially reducing the MRI signal intensity of the tumor region at 10 min postinjection. With their dual plasmonic-magnetic functionality, these Au@MgFe2O4 nanohybrids hold great promise not only in the biomedical field but also in the areas of catalysis and optical sensing.

| S-EPMC8771950 | biostudies-literature

Self-assembled gemcitabine-gadolinium nanoparticles for magnetic resonance imaging and cancer therapy.

Project description:Nanoparticles with combined diagnostic and therapeutic functions are promising tools for cancer diagnosis and treatment. Here, we demonstrate a theranostic nanoparticle that integrates an active gemcitabine metabolite and a gadolinium-based magnetic resonance imaging agent via a facile supramolecular self-assembly synthesis, where the anti-cancer drug gemcitabine-5'-monophosphate (a phosphorylated active metabolite of the anti-cancer drug gemcitabine) was used to coordinate with Gd(III) to self-assemble into theranostic nanoparticles. The formulation exhibits a strong T1 contrast signal for magnetic resonance imaging of tumors in vivo, with enhanced retention time. Furthermore, the nanoparticles did not require other inert nanocarriers or excipients and thus had an exceptionally high drug loading (55 wt%), resulting in the inhibition of MDA-MB-231 tumor growth in mice.Statement of significanceRecent advances in nanoparticle-based drug delivery systems have spurred the development of "theranostic" multifunctional nanoparticles, which combine therapeutic and diagnostic functionalities in a single formulation. Developing simple and efficient synthetic strategies for the construction of nanotheranostics with high drug loading remains a challenge. Here, we demonstrate a theranostic nanoparticle that integrates high loadings of an active gemcitabine metabolite and a gadolinium-based magnetic resonance imaging agent via a facile synthesis. The nanoparticles were better T1 contrast agents than currently used Gd-DTPA and had prolonged retention in tumor. Moreover they exhibited enhanced in vivo antitumor activity compared to free drug in a breast cancer xenograft mouse model. The strategy provides a scalable way to fabricate nanoparticles that enables enhancement of both therapeutic and diagnostic capabilities.

| S-EPMC4777675 | biostudies-literature

Hyaluronic Acid-Functionalized Gadolinium Oxide Nanoparticles for Magnetic Resonance Imaging-Guided Radiotherapy of Tumors.

Project description:Inaccuracy localization and intrinsic radioresistance of solid tumors seriously hindered the clinical implementation of radiotherapy. In this study, we fabricated hyaluronic acid-functionalized gadolinium oxide nanoparticles (HA-Gd2O3 NPs) via one-pot hydrothermal process for effective magnetic resonance (MR) imaging and radiosensitization of tumors. By virtue of HA functionalization, the as-prepared HA-Gd2O3 NPs with a diameter of 105 nm showed favorable dispersibility in water, low cytotoxicity, and excellent biocompatibility and readily entered into the cytoplasm of cancer cells by HA receptor-mediated endocytosis. Importantly, HA-Gd2O3 NPs exhibited high longitudinal relaxivity (r1) 6.0 mM-1S-1 as MRI contrast agents and radiosensitization enhancement in a dose-dependent manner. These finds demonstrated that as-synthesized HA-Gd2O3 NPs as bifunctional theranostic agents have great potential in tumors diagnosis and radiotherapy.

| S-EPMC7183523 | biostudies-literature

Polydopamine coated manganese oxide nanoparticles with ultrahigh relaxivity as nanotheranostic agents for magnetic resonance imaging guided synergetic chemo-/photothermal therapy.

Project description:Mn-based nanoparticles have been regarded as a new class of probes for magnetic resonance imaging (MRI), but their low relaxivity is the major obstacle for applications in vivo. Herein, we designed and constructed a multifunctional nanotheranostic (FA-Mn3O4@PDA@PEG) for MRI guided combinatorial chemo-/photothermal therapy (PTT) for cancer. The ultrahigh relaxivity of 14.47 mM-1 s-1 makes the nanotheranostic an excellent contrast agent for MRI in vitro and in vivo, and provides comprehensive information for tumor diagnosis. When irradiated with an 808 nm NIR laser, FA-Mn3O4@PDA@PEG exhibits a remarkably improved and synergistic therapeutic effect compared to PTT or chemotherapy alone, providing high therapeutic efficiency and low side effects of drugs. These findings are of great interest and will inspire us to develop highly effective MRI guided synergetic chemo-/photothermal therapy for cancer treatment.

| S-EPMC5355856 | biostudies-literature

Gadolinium-Coated Mesoporous Silica Nanoparticle for Magnetic Resonance Imaging.

Project description:Magnetic resonance molecular imaging can provide anatomic, functional and molecular information. However, because of the intrinsically low sensitivity of magnetic resonance imaging (MRI), high-performance MRI contrast agents are required to generate powerful image information for image diagnosis. Herein, we describe a novel T 1 contrast agent with magnetic-imaging properties facilitated by the gadolinium oxide (Gd2O3) doping of mesoporous silica nanoparticles (MSN). The size, morphology, composition, MRI relaxivity (r 1 ), surface area and pore size of these nanoparticles were evaluated following their conjugation with Gd2O3 to produce Gd2O3@MSN. This unique structure led to a significant enhancement in T 1 contrast with longitudinal relaxivity (r 1 ) as high as 51.85 ± 1.38 mM-1s-1. Gd2O3@MSN has a larger T 1 relaxivity than commercial gadolinium diethylene triamine pentaacetate (Gd-DTPA), likely due to the geometrical confinement effect of silica nanoparticles. These results suggest that we could successfully prepare a novel high-performance T 1 contrast agent, which may be a potential candidate for in-vivo MRI.

| S-EPMC8885602 | biostudies-literature

A novel vector for magnetic resonance imaging-guided chemo-photothermal therapy for cancer.

Project description:As an effective strategy for oncotherapy, developing efficacious drug delivery systems for cancer combination therapy remains a major challenge. To improve nanodrug biocompatibility and composite function facilitating their clinical conversion application, a novel nanocarrier was presented by a facile method through conjugating humic acid with gadolinium ions to synthesize HA-Gd with good biocompatibility and dispersity. HA-Gd exhibited high photothermal conversion efficiency up to 38%, excellent photothermal stability, and high doxorubicin (DOX) loading capacity (93%) with pH-responsive release properties. HA-Gd loading DOX showed a combined chemo-photothermal inhibitory effect on tumor cells. Compared with lipid-DOX, HA-Gd-DOX had a more significant inhibitory effect on tumor growth and fewer side effects. T1-weighted MRI contrast toward tumor tissue provided HA-Gd with an MRI-based cancer diagnosis. This study revealed the great potential of humic acids as a novel vector for developing more drug carriers with desirable functions for clinical anticancer therapy.

| S-EPMC9618661 | biostudies-literature

Photoacoustic and magnetic resonance imaging-based gene and photothermal therapy using mesoporous nanoagents.

Project description:The integration of photothermal therapy (PTT) with gene therapy (GT) in a single nanoscale platform demonstrates great potential in cancer therapy. Porous iron oxide nanoagents (PIONs) are widely used as magnetic nanoagents in the drug delivery field and also serve as a photothermal nanoagent for photothermal therapy. However, the therapeutic efficacy of PIONs-mediated GT has not been studied. The long noncoding RNA (lncRNA) CRYBG3 (LNC CRYBG3), a lncRNA induced by heavy ion irradiation in lung cancer cells, has been reported to directly bind to globular actin (G-actin) and cause degradation of cytoskeleton and blocking of cytokinesis, thus indicating its potential for use in GT by simulating the effect of heavy ion irradiation and functioning as an antitumor drug. In the present study, we investigated the possibility of combining PIONs-mediated PTT and LNC CRYBG3-mediated GT to destroy non-small cell lung cancer (NSCLC) cells both in vitro and in vivo. The combination therapy showed a high cancer cell killing efficacy, and the cure rate was better than that achieved using PTT or GT alone. Moreover, as a type of magnetic nanoagent, PIONs can be used for magnetic resonance imaging (MRI) and photoacoustic imaging (PAI) both in vitro and in vivo. These findings indicate that the new combination therapy has high potential for cancer treatment.

| S-EPMC8586268 | biostudies-literature

Gadolinium-Loaded Viral Capsids as Magnetic Resonance Imaging Contrast Agents.

Project description:Polymeric nanohybrid P22 virus capsids were used as templates for high density Gd3+ loading to explore magnetic field-dependent (0.5-7.0 T) proton relaxivity. The field-dependence of relaxivity by the spatially constrained Gd3+ in the capsids was similar when either the loading of the capsids or the concentration of capsids was varied. The ionic longitudinal relaxivity, r1, decreased from 25-32 mM-1 s-1 at 0.5 T to 6-10 mM-1 s-1 at 7 T. The ionic transverse relaxivity, r2, increased from 28-37 mM-1 s-1 at 0.5 T to 39-50 mM-1 s-1 at 7 T. The r2/r1 ratio increased linearly with increasing magnetic field from about 1 at 0.5 T, which is typical of T1 contrast agents, to 5-8 at 7 T, which is approaching the ratios for T2 contrast agents. Increases in electron paramagnetic resonance line widths at 80 and 150 K and higher microwave powers required for signal saturation indicate enhanced Gd3+ electron spin relaxation rates for the Gd3+-loaded capsids than for low concentration Gd3+. The largest r2/r1 at 7 T was for the highest cage loading, which suggests that Gd3+-Gd3+ interactions within the capsid enhance r2 more than r1.

| S-EPMC5645056 | biostudies-literature

Cationic gadolinium chelate for magnetic resonance imaging of cartilaginous defects.

Project description:The ability to detect meniscus defects by magnetic resonance arthrography (MRA) can be highly variable. To improve the delineation of fine tears, we synthesized a cationic gadolinium complex, (Gd-DOTA-AM4 )(2+) , that can electrostatically interact with Glycosaminoglycans (GAGs). The complex has a longitudinal relaxivity (r1) of 4.2 mM(-1) s(-1) and is highly stable in serum. Its efficacy in highlighting soft tissue tears was evaluated in comparison to a clinically employed contrast agent (Magnevist) using explants obtained from adult bovine menisci. In all cases, Gd-DOTA-AM4 appeared to improve the ability to detect the soft tissue defect by providing increased signal intensity along the length of the tear. Magnevist shows a strong signal near the liquid-meniscus interface, but much less contrast is observed within the defect at greater depths. This provides initial evidence that cationic contrast agents can be used to improve the diagnostic accuracy of MRA. Copyright © 2016 John Wiley & Sons, Ltd.

| S-EPMC4892988 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data